The Importance of Access to Care for Multiple Myeloma in Community Settings

Video

For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.

Communication with and continued education of community partners is key when treating patients with multiple myeloma. Access to care is often limited, so being able to reach patients in the community setting is paramount, according to Ashely E. Rosko, MD.

CancerNetwork® was able to speak with Rosko during an Around the Practice® program that she moderated. In addition to the importance of access, she also highlighted the various resources patients should seek while undergoing treatment so they don’t feel alone in facing their diagnosis. Rosko is an associate professor in the Department of Internal Medicine at The Ohio State University, medical director of the Oncogeriatric Program at The Ohio State University Comprehensive Cancer Center – The James, and co-director of the Cancer and Aging Resiliency (CARE) Clinic at The James.

Transcript:

The thing that I’d like to highlight is that multiple myeloma isn’t an uncommon disease. Oftentimes, myeloma is treated and diagnosed in the community [setting]. We work closely with our community partners to be able to deliver advanced care for patients. Oftentimes, patients come to us for a consultation or a second opinion, and then we get them back to the community to be able to get their care locally.

When it comes to uncommon diseases in an ever-changing and rapidly changing field, it’s important for patients to be able to seek care at a comprehensive cancer center, and also to be able to get their care locally. Communication is enhanced with our partners in the community, and we wouldn’t be able to do this when it comes to myeloma care delivery without them.

My final take when it comes to multiple myeloma is that we are here as a resource to be able to provide knowledge and advances in the field and, at the same time, allow patients to be able to stay in their hometown and in their community to be able to get the care and advances when it comes to a rapidly changing field like multiple myeloma.

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
4 experts in this video
Related Content